Breaking News Instant updates and real-time market news.

RNN

Rexahn

$6.82

1.33 (24.23%)

12:57
04/16/19
04/16
12:57
04/16/19
12:57

Rexahn soars after finding Chinese partner for cancer drug RX-3117

Rexahn Pharmaceuticals and BioSense Global announced earlier today a collaboration and license agreement to advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China. Shares of Rexahn are up 28%, or $1.49, to $6.87 in afternoon trading. Under the agreement, Rexahn will grant BioSense an exclusive license to develop and commercialize RX-3117 in Greater China. Rexahn will receive an upfront payment and will be eligible to receive additional development, regulatory and commercial milestones up to a total of $226M contingent on achieving regulatory and commercial goals related to pancreatic cancer and additional indications. The upfront payment consists of an aggregate of $3M, $1.5M of which has been paid and the remaining $1.5M of which is due August 24. Rexahn will also be eligible to receive tiered royalties in the low double digits to mid-teens on annual net sales in the territory. The companies will collaborate to develop RX-3117 for pancreatic cancer and other indications. BioSense will fund all activities related to the development and commercialization of RX-3117 in Greater China and will initiate a Phase 2 study to evaluate the drug candidate in up to three additional indications not previously studied by Rexahn. "Rexahn is focused on developing novel therapies for people with difficult-to-treat cancers. This partnership will enable us to extend the development of RX-3117 to patients in Greater China and also to evaluate RX-3117 in additional indications in collaboration with BioSense," said Douglas Swirsky, President and CEO of Rexahn.

RNN Rexahn
$6.82

1.33 (24.23%)

02/05/19
HCWC
02/05/19
NO CHANGE
Target $10
HCWC
Buy
Rexahn price target lowered to $10 from $17 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Rexahn Pharmaceuticals to $10 following the company's equity raise and keeps a Buy rating on the shares.
12/06/18
HCWC
12/06/18
NO CHANGE
Target $17
HCWC
Buy
Rexahn focusing on 'promising' oncology pipeline, says H.C. Wainwright
After Rexahn announced a restructuring aimed at reducing overall operating costs and prioritizing resources towards leading assets RX-3117 and RX-5902, H.C. Wainwright analyst Joseph Pantginis noted that he believes the company's recently announced safety and efficacy data from its ongoing Phase 2a trial testing RX-3117 in combination with Abraxane were "impressive, especially considering the comparison" with the current standard of care. The analyst, who thinks the stock's current valuation represents a "significant disconnect" to the underlying opportunity for the company's " promising oncology pipeline," keeps a Buy rating on Rexahn shares with a $17 price target.
10/04/18
IFSG
10/04/18
UPGRADE
IFSG
Strong Buy
Rexahn upgraded to Strong Buy from Outperform at IFS Securities
10/02/18
HCWC
10/02/18
NO CHANGE
Target $19.5
HCWC
Buy
'Bright light' shining on Rexahn's RX-3117/Abraxane combo, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis notes that Rexahn and investigators announced positive interim Phase 2a data from the ongoing study combining RX-3117 with Abraxane in front-line pancreatic cancer. The analyst believes the "bright light" is now shining on RX-3117/Abraxane combo, and should get brighter with subsequent updates. Overall, Pantginis believes that the shares current valuation represents a significant disconnect to the underlying opportunity for RX-3117 and RX-5902. He reiterates a Buy rating and $19.50 price target on the stock.

TODAY'S FREE FLY STORIES

HMST

HomeStreet

$28.08

(0.00%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Hot Stocks
HomeStreet 'disappointed' over Blue Lion's director nominations, proposals »

HomeStreet issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

PYPL

PayPal

$107.92

1.01 (0.94%)

, FB

Facebook

$183.84

0.07 (0.04%)

11:50
04/24/19
04/24
11:50
04/24/19
11:50
Earnings
Fly Intel: What to watch in PayPal earnings report »

PayPal (PYPL) is…

PYPL

PayPal

$107.92

1.01 (0.94%)

FB

Facebook

$183.84

0.07 (0.04%)

EBAY

eBay

$38.45

1.79 (4.88%)

JPM

JPMorgan

$113.45

-0.29 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 09

    May

  • 14

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 11

    Jun

  • 16

    Jul

AMRN

Amarin

$18.32

-0.07 (-0.38%)

11:45
04/24/19
04/24
11:45
04/24/19
11:45
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 06

    May

11:45
04/24/19
04/24
11:45
04/24/19
11:45
General news
Treasury's $20 B FRN auction was awarded at a high discount margin of 0.139% »

Treasury's $20 B FRN…

LRN

K12

$31.11

-5.115 (-14.12%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Recommendations
K12 analyst commentary  »

Barrington reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$262.87

-0.98 (-0.37%)

, SSNLF

Samsung

$0.00

(0.00%)

11:40
04/24/19
04/24
11:40
04/24/19
11:40
Earnings
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

TSLA

Tesla

$262.87

-0.98 (-0.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

CAT

Caterpillar

$138.82

-3.26 (-2.29%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar: Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

GWW

Grainger

$292.75

-0.46 (-0.16%)

11:37
04/24/19
04/24
11:37
04/24/19
11:37
Hot Stocks
Grainger authorizes repurchase of additional 5M shares »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BKU

BankUnited

$35.97

0.24 (0.67%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Downgrade
BankUnited rating change  »

BankUnited downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 15

    May

GWW

Grainger

$292.73

-0.48 (-0.16%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
Hot Stocks
Grainger raises dividend by 6% to $1.44 per share »

W.W. Grainger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BBY

Best Buy

$75.08

1.48 (2.01%)

, PG

Procter & Gamble

$104.47

1.28 (1.24%)

11:36
04/24/19
04/24
11:36
04/24/19
11:36
On The Fly
Best Buy, P&G, Snap upgrades among today's top analyst calls »

Check out today's top…

BBY

Best Buy

$75.08

1.48 (2.01%)

PG

Procter & Gamble

$104.47

1.28 (1.24%)

SNAP

Snap

$11.20

-0.79 (-6.59%)

KHC

Kraft Heinz

$32.73

-0.365 (-1.10%)

AAPL

Apple

$208.23

0.73 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 23

    May

  • 29

    May

  • 03

    Jun

TEVA

Teva

$14.98

0.07 (0.47%)

, MYL

Mylan

$26.47

-0.13 (-0.49%)

11:35
04/24/19
04/24
11:35
04/24/19
11:35
Recommendations
Teva, Mylan, Novartis analyst commentary at Wells Fargo »

Sandoz results should not…

TEVA

Teva

$14.98

0.07 (0.47%)

MYL

Mylan

$26.47

-0.13 (-0.49%)

NVS

Novartis

$78.35

2.51 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 08

    May

  • 22

    May

  • 31

    May

YPF

YPF

$14.54

-0.35 (-2.35%)

11:35
04/24/19
04/24
11:35
04/24/19
11:35
Options
YPF put volume heavy and directionally bearish »

Bearish flow noted in YPF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

CAT

Caterpillar

$138.44

-3.64 (-2.56%)

11:32
04/24/19
04/24
11:32
04/24/19
11:32
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar to discuss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

11:30
04/24/19
04/24
11:30
04/24/19
11:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

CAT

Caterpillar

$138.79

-3.29 (-2.32%)

11:24
04/24/19
04/24
11:24
04/24/19
11:24
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar says flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

TSN

Tyson Foods

$73.67

-0.78 (-1.05%)

, BYND

Beyond Meat

$0.00

(0.00%)

11:21
04/24/19
04/24
11:21
04/24/19
11:21
Periodicals
Tyson Foods quietly sells stake in Beyond Meat, Axios reports »

Tyson Foods (TSN) has…

TSN

Tyson Foods

$73.67

-0.78 (-1.05%)

BYND

Beyond Meat

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 02

    May

IVZ

Invesco

$21.55

-0.07 (-0.32%)

11:20
04/24/19
04/24
11:20
04/24/19
11:20
Options
Call buy in Invesco longest-dated options contracts ahead of earnings »

Call buy in Invesco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

ZTO

ZTO Express

$19.98

0.18 (0.91%)

11:19
04/24/19
04/24
11:19
04/24/19
11:19
Conference/Events
ZTO Express management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 15

    May

CAT

Caterpillar

$138.70

-3.38 (-2.38%)

11:19
04/24/19
04/24
11:19
04/24/19
11:19
Hot Stocks
Caterpillar CFO sees stronger results in 2H vs. 1H »

Expects to repurchase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

CAT

Caterpillar

$138.58

-3.5 (-2.46%)

11:18
04/24/19
04/24
11:18
04/24/19
11:18
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar CFO says has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
04/24/19
04/24
11:17
04/24/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
04/24/19
04/24
11:16
04/24/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$138.12

-3.96 (-2.79%)

11:13
04/24/19
04/24
11:13
04/24/19
11:13
Hot Stocks
Breaking Hot Stocks news story on Caterpillar »

Caterpillar CFO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

11:13
04/24/19
04/24
11:13
04/24/19
11:13
Conference/Events
CLSA China consumer luxury analyst to hold a luncheon meeting »

China Consumer Luxury…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.